When it comes to medication adherence in psychiatry and oncology trials, the stakes are high – not taking medicines as prescribed can have life-altering or even life-threatening consequences. As such, we often assume almost perfect adherence. Unfortunately, this could not … Read More
Breaking News
Considerations for Ensuring Optimal Digital Adherence Monitoring
It’s no secret, recruiting clinical trial participants is difficult, time-consuming, and considerably expensive, all while dropout rates are notoriously high across therapeutic areas. Whatever the motive for dropout, the impact is huge. Trials can become underpowered and may not have … Read More
Mitigating the Risk of Trial Failure with Digital Adherence Monitoring
Drug development is inherently risky, with some analysis showing that just 13.8% of products that enter industry-sponsored Phase I trials go on to obtain FDA approval.1 Of course, the exact figure varies across therapy areas and development stages, but it is … Read More
AARDEX and Schreiner MediPharm reinforce their collaboration to Enhance Medication Adherence Management
AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence … Read More
AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence
AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence … Read More
ONdrugDelivery October Issue is now live which includes a contribution of AARDEX Group
AARDEX’s Scientific Lead Bernard Vrijens and Biocorp’s business development director Arnaud Guillet give some details about their companies alliance. They explain how Biocorp’s Injay connected prefilled syringe (PFS) combined with AARDEX’s MEMS Adherence Software provides a mean to tackle the … Read More
AARDEX Group partners with BIOCORP to extend digital solutions for precision medication adherence
AARDEX Group, the world leader in medication adherence solutions, today announced a strategic partnership with BIOCORP, a French company specialized in the design, development and manufacture of innovative medical devices. … Read More
AARDEX announces the world’s first DIGITAL MEDICATION ADHERENCE MONITORING solution fully integrated in the clinical trial platform by a top 10 pharma company.
AARDEX is proud to announce the integration of its MEMS® Adherence Software by a major pharmaceutical company. It’s the first end-to-end integration of electronically compiled dosing histories using smart packages from interactive response technology (IRT) into electronical data capture systems … Read More
How digital medication adherence monitoring increases the impact of innovative adherence research?
MEMS® has been a part of successful adherence research for more than 30 years.Download this adherence compendium and find out how digital medication adherence monitoring increases the impact of academic research findings.
AARDEX Group announces the opening of a new office in the U.S.
By establishing itself in the U.S., the Group aims to strengthen its business and maintain its position as market leader in digital adherence monitoring systems. Joe Keenan will lead the business development for the pharma and biotech industry in North America. … Read More